2001
DOI: 10.1182/blood.v97.4.867
|View full text |Cite
|
Sign up to set email alerts
|

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

Abstract: To determine the risk factors and outcomes associated with rising cytomegalovirus (CMV) antigenemia levels during preemptive therapy among stem cell allograft recipients, 119 patients with CMV antigenemia were studied. Patients were prospectively monitored for CMV antigenemia weekly; those with positive findings on antigenemia tests were treated with intravenous ganciclovir (5 mg/kg twice daily for 1 week, followed by 5 mg/kg per day for 5-6 d/wk). While on therapy, 47 of 119 (39%) patients demonstrated increa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

9
130
2
1

Year Published

2002
2002
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 201 publications
(142 citation statements)
references
References 21 publications
9
130
2
1
Order By: Relevance
“…In addition to ganciclovir therapy, intensive immunosuppressive therapy including high-dose steroids and ATG could be a risk factor for recurrent CMV infection and subsequent late CMV diseases due to delaying CMV-specific immune reconstitution. 34,35 To totally evaluate the efficacy and disadvantages of a reduced dose of ganciclovir, a comparative study should be performed.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to ganciclovir therapy, intensive immunosuppressive therapy including high-dose steroids and ATG could be a risk factor for recurrent CMV infection and subsequent late CMV diseases due to delaying CMV-specific immune reconstitution. 34,35 To totally evaluate the efficacy and disadvantages of a reduced dose of ganciclovir, a comparative study should be performed.…”
Section: Discussionmentioning
confidence: 99%
“…[3][4][5] However, some unsolved problems remain, not least that the procedure remains unstandardized. Whereas antigenemia assays have been almost completely standardized using an anti-pp65 antibody, 6,7 real-time PCR assays have been carried out using a variety of procedures: the target region being amplified by real-time PCR assay differs in each report, some target the immediate early protein (IE), while others target glycoprotein B (gB) or the US17 region, 2,4,8 and primers and probes for the target region also differ. 2,9,10 Few reports have been published which compare the viral load detected by real-time PCR assay targeting distinct genomic regions.…”
Section: Real-time Pcrmentioning
confidence: 99%
“…8 In this study, rising antigenemia was defined as the observation of an increase in the antigenemia level to more than double that of the baseline after GCV 10 mg/kg/day for more than 7 days. In our subjects, 25 episodes of rising antigenemia occurred in 22 patients.…”
Section: Rising Antigenemiamentioning
confidence: 99%